Bright and early this morning, Roche Group (OTC: RHHB) announced first-half earnings and upped its annual earnings goal, thanks to impressive sales of Tamiflu. Roche's first-half profit (it only reports earnings twice) dropped 29% to $3.8 billion as the company was hit by costs related to its purchase of Genentech. That said, Roche upped its earnings guidance and forecast double-digit core earnings growth in both 2009 and 2010 -- the earlier forecast called for earnings to stay at 2008 levels.
generic medicine posts
FeedRoche sees solid first-half profits
The dumbing down of the global economy
A graph from the May 2008 issue of Harvard Business Review tells a story about the dumbing down of the global economy.
From an article, Rebuilding the R&D Engine in Big Pharma [subscription required] the graph shows the total shareholder returns for various industries in two time periods: from 1985 to 2000 and from 2001 to 2007. Here are three of the leading sectors from 1985 to 2000 (average annual shareholder returns are in parentheses):
- Pharmaceuticals (20.0%)
- Financials (18.8%)
- IT (17.4%)
Between 2001 and 2007, three of the leading sectors were:
- Energy (15.2%)
- Materials (14.3%)
- Financials (7.0%)
Closing Bell: Dubai sends jitters throughout the market (S, BBY)
Heinz looking good after the second quarter?
Why isn't Bank of America updating its shareholders on CEO situation?
